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ABSTRACT 
 
Background: Traditional monitoring of blood pressure in hypertensive pregnant women 
requires frequent visits to the maternity outpatient services. Home blood-pressure monitoring 
(HBPM) could offer a cost-saving alternative that is acceptable to patients. The main 
objective of this study was to undertake a health economic analysis of HBPM compared with 
traditional monitoring in hypertensive pregnant women. 
 
Methods: This was a case–control study. Cases were pregnant women with hypertension 
who had HBPM with or without the adjunct of a smartphone app, via a specially designed 
pathway. The control group were managed as per existing hospital guidelines. Specific 
outcome measures were the number of outpatient visits, inpatient bed stays and 
investigations performed. Maternal, fetal and neonatal adverse outcomes were also 
recorded. Health economic analysis was performed using two methods: direct cost 
comparison of the study dataset and process scenario modelling.  
 
Results: There were 108 women in the HBPM group, of whom 29 recorded their results on 
the smartphone app (App-HBPM) and 79 in their notes (Non-app HBPM). The control group 
comprised of 58 patients. There were significantly more women with chronic hypertension in 
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the HBPM group (49.1% vs 25.9%, P = 0.004). The HBPM group had significantly longer 
duration of monitoring (9 weeks vs 5 weeks P = 0.004) and started monitoring from an earlier 
gestation (30 weeks vs 33.6 weeks, P = 0.001). Despite these differences, the mean saving 
per week for HBPM compared with the control group was £200.69. For the App-HBPM 
cohort, the saving per week compared with the control group was £286.53. The process 
modelling method predicted savings of between £98.32 and £245.80 per week using HBPM 
compared to the traditional monitoring.  
 
Conclusion: HBPM in hypertensive pregnancies appears to be cost-saving compared with 
traditional monitoring, without compromising maternal, fetal or neonatal safety. Larger 
studies are required to confirm these findings. 
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INTRODUCTION 
 
Hypertensive disorders such as gestational hypertension (GH), chronic hypertension and 
pre-eclampsia (PE) complicate up to 10% of pregnancies. The incidence of PE is 2–8%.1-3 
While maternal mortality due to PE is decreasing in the UK, it remains a leading cause of 
direct maternal deaths worldwide as well as causing maternal, fetal and neonatal morbidity. 
The most recent ‘Mothers and Babies: Reducing Risk through Audits and Confidential 
Enquiries across the UK’ (MBRRACE-UK) report made several recommendations, including 
the need for an increased schedule of checks for hypertensive women and the need for 
prompt control of hypertension.4-6 
 
Current care for women who develop hypertensive disorders of pregnancy centres on 
outpatient attendance to a day assessment unit (DAU) at their maternity hospital for blood-
pressure monitoring and urine testing, as well as blood tests and fetal monitoring 
(cardiotocography and/or ultrasound scan), if indicated. The frequency of visits depends on 
the underlying diagnosis but is often two to three times a week.7 Admission to an antenatal 
ward is common place when initiating medication for uncontrolled blood pressure or if there 
is suspicion of PE. This frequent monitoring can represent a source of anxiety to these 
women and their families, it is demanding for them in terms of time, transport costs and work 
absence, and has significant cost implications for limited healthcare resources.  
 
Home blood-pressure monitoring (HBPM) is used extensively outside of pregnancy and is an 
accurate and patient-acceptable alternative to clinic visits. HBPM is recommended by the 
‘British Hypertension Society’ and ‘National Institute for Health Research’ who have 
produced evidence to support its implementation.8,9 They advise that more research is 
needed into HBPM in pregnancy which reflects the need for this innovation to be transferred 
to the obstetric setting.8,9 The American College of obstetricians and Gynaecologists 
advocates the use of HBPM in patients with chronic hypertension and other professional 
bodies recognise its potential.8,10,11 HBPM is acceptable to pregnant patients and does not 
increase anxiety.12,13  
 
The main objective of this study was to undertake a health economic analysis of the cost-
effectiveness of HBPM compared with traditional monitoring in hypertensive pregnancies.  
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METHODS 
 
Population and Study Design 
This was a cost-minimisation study involving a cohort of hypertensive pregnant women 
enrolled on a HBPM pathway and a control group managed according to the traditional 
pathway of regular DAU visits for blood-pressure monitoring. Since the patients presented 
equivalent health outcomes and the main aim of the study was to assess cost savings of the 
new pathway compared with the conventional one, we called this study a cost-minimisation 
study. The study perspective was the direct costs to the healthcare system. Patients 
presented either via referral to the Hypertension Clinic or to the DAU at St George’s 
University Hospital NHS Foundation Trust between December 2013 and November 2016. 
Pregnant women with a history of pre-pregnancy hypertension or at increased risk of 
developing hypertension in pregnancy, systolic blood pressure ≥140mmHg, diastolic blood 
pressure ≥90mmHg, proteinuria ≤1+ on urine dipstick, normal full blood count, liver and renal 
function blood tests, English speaking were included in the study. Exclusion criteria were 
maternal age <16 years at booking, systolic blood pressure >155mmHg, diastolic blood 
pressure >100mmHg, proteinuria ≥2+ on urine dipstick, severe pre-eclampsia, intrauterine 
fetal growth restriction, significant mental health concerns, inability to give valid consent or 
language barrier. The above blood pressure parameters were selected in order to avoid 
patients developing severe hypertension at home. This is in line with the recommendation of 
hospital admission for systolic blood pressure of 160mmHg or diastolic blood pressure of 
110mmHg.7 Severe PE was diagnosed in the presence of oliguria of less than 500mL urine 
output in 24 h, cerebral or visual disturbance, pulmonary oedema, epigastric or right upper 
quadrant pain, impaired liver function (twice the upper limit of normal levels for AST and/or 
ALT), thrombocytopenia (platelet count < 100,000/mm3). 
The diagnosis of PE and GH was made according to the criteria of the International Society 
for the Study of Hypertension in Pregnancy.14 GH was diagnosed in the presence of systolic 
blood pressure ≥ 140mmHg and/or the diastolic blood pressure ≥ 90mmHg on at least two 
occasions 4 h apart developing after 20 weeks of gestation in previously normotensive 
women in the absence of significant proteinuria. In PE there should be GH with proteinuria of 
300mg or more in 24 h, or two readings of at least ++ on dipstick analysis of midstream or 
catheter urine specimens if no 24-h collection is available. PE superimposed on chronic 
hypertension was diagnosed if significant proteinuria (as defined above) developed after 20 
weeks of gestation in women with known chronic hypertension (history of hypertension 
before conception or presence of hypertension at the booking visit before 20 weeks of 
gestation in the absence of trophoblastic disease). The diagnosis of chronic hypertension 
was made when there was a documented presence of chronic non-GH prior to this 
pregnancy, or history of anti-hypertensive medication prior to 20+0 weeks. The diagnosis of 
White-coat Hypertension was made when there were confirmed high blood-pressure 
recordings in the hospital/clinic with normal readings on HBPM or ambulatory monitoring. 
 
Home blood-pressure monitoring pathway 
Women eligible to the home monitoring of pregnancy hypertension pathway were counselled 
and trained by a specialist midwife and supplied with an automated Microlife® blood-pressure 
machine (MicrolifeCorporation, Taipei, Taiwan), which has been validated in pregnancy and 
PE15, and with urine dipsticks. They were taught how to measure their blood pressure 
accurately and record readings in their notes or on a specially designed smartphone app 
(Hampton Medical, Trakka Medical, UK). Women were given a personalized schedule of 
monitoring based on their underlying diagnosis, which was reviewed by the midwife every 1–
2 weeks. While the schedule varied between patients, the frequency of monitoring complied 
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with National Institute for Health and Care Excellence (NICE) guidance on hypertension in 
pregnancy.7 A typical regime for a woman with well-controlled chronic hypertension would be 
to measure blood pressure two or three times a week and be reviewed every 2–3 weeks, 
whereas a woman initiating new treatment would be asked to measure blood pressure twice 
a day and reviewed 1 week later. The same specialist midwife reviewed patients at the 
interim visits to reduce bias. 
 
The innovative application (App) for smartphone users was developed to enable women to 
record their blood pressure and urinalysis results and any symptoms at home. The App has 
a set of trigger questions to determine whether they are developing PE, such as the 
presence of headache, epigastric pain or visual symptoms. An alert flashes up on the screen 
if one of the trigger questions have indicated that the woman might be developing PE or the 
recorded blood pressure or urine results are above the pre-defined thresholds, advising the 
woman to contact the hospital immediately. Alternatively, if the woman enters blood pressure 
and urinalysis results which are below the pre-defined thresholds, and does not answer ‘yes’ 
to the trigger questions, the App will advise the patient to continue on the routine home 
monitoring care pathway. 
Patients in the control group presented either directly to the DAU or to the Antenatal Clinic. 
They were managed according to the hospital protocol and had all blood-pressure checks 
performed in the DAU.  
 
Data collection and planned analysis 
All individual patient records as well as maternity, ultrasound and neonatal databases were 
reviewed to collect data on patient demographics, starting and end diagnosis, birth details 
and adverse maternal, fetal and neonatal outcomes. Adverse maternal outcomes included 
acute renal failure (maternal serum creatinine level above 100micromol/L antenatally, or 
above 130micromol/L postnatally) or need for dialysis, acute myocardial ischaemia, need for 
a third intravenous agent to control blood pressure (e.g., in addition to labetalol and 
hydralazine), hypertensive encephalopathy (altered mental status with characteristic cerebral 
imaging), cortical blindness, retinal detachment, stroke (ischemic or hemorrhagic), 
pulmonary oedema or adult respiratory distress syndrome (defined as characteristic 
pulmonary imaging in addition to oxygen requirement), need for mechanical ventilatory 
support (other than for Cesarean section), disseminated intravascular coagulation, 
thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome, acute fatty liver, liver 
haematoma or rupture, placental abruption and maternal death. Adverse fetal outcomes 
included preterm delivery (< 37+0 weeks’ gestation), small for gestational age (birthweight 
<10th centile for gestational age, fetal growth restriction (birthweight < 5th centile for 
gestational age) and antepartum or intrapartum fetal death. Adverse neonatal outcomes 
included neonatal death, respiratory distress syndrome, intraventricular haemorrhage, 
necrotising enterocolitis, bronchopulmonary dysplasia, periventricular leukomalacia, 
retinopathy of prematurity, seizures and admission to the neonatal unit for more than 48 h 
(for full-term infants). 
Data on the utilisation of health resources were recorded, including the duration of blood-
pressure monitoring in weeks, the number of blood-pressure-related visits to the DAU, the 
Hypertension Clinic, the General Practitioner (GP) and out-of-hours maternity triage and 
blood-pressure-related hospital admissions to the antenatal or postnatal ward or to the High 
Dependency Unit (HDU) for severe PE. The number of investigations for blood-pressure-
related reasons was recorded, including hematological and biochemistry tests of maternal 
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blood and ultrasound scans for assessment of fetal growth. Administration of corticosteroids 
for fetal lung maturity and magnesium sulphate for severe PE was also recorded.  
The healthcare economic evaluation was performed using two methods: a direct cost 
comparison of the dataset between the two groups and process scenario modelling. The 
cost inputs were derived from a series of costing templates based on NICE guidelines, NHS 
practices’ reports as well as recent scientific research papers with high impact factor (Table 
1).15-21 All the costs were collected in or inflated to 2015 values. The processing modelling 
was based on two common scenarios: in the first, a woman develops GH and requires 
ongoing monitoring on an outpatient basis; in the second, a woman requires admission for 
control of hypertension. The differences between the scenarios based on traditional and 
HBPM are shown in Table 2. The calculations performed for the process modelling are 
shown in Figure 1. The following assumptions were made to estimate costs: the midwife 
would be of band 6 grading (this relates to payscale and represents the banding of most 
midwives working in this area), the doctor would be either registrar/associate specialist or a 
consultant (the mean hourly rate was used) and every clinic and consultation appointment 
was assumed to have a duration of 1 hour apart from the Hypertension clinic and extra 
consultation sessions which were calculated as 30 minutes.  
In the UK, healthcare is free at the point of access and patients do not have to pay hospital 
bills. For this reason, bills for individual patients are not created and therefore could not be 
used in this analysis. Hospitals use tariffs for their services based on a coding system in 
order to generate funding from the state. However, this information is not easy to 
extrapolate, does not cover all the items we considered and is dependent on the accuracy of 
the information entered. Therefore, we decided on the above methods for assessment of 
cost to ensure a robust review of each patient’s case. 
 
Statistical analysis 
Categorical variables were described as n (%) and continuous variables as median 
(interquartile range). The chi-Square test, or Fisher’s exact test when appropriate, was used 
to compare the categorical variables. The Kruskal-Wallis test and Mann–Whitney U-test 
were used for the analysis of continuous data. P < 0.05 was deemed statistically significant. 
All statistical analyses were performed using the IBM SPSS Statistics version 24 (IBM 
Corporation, Armonk, NY, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
RESULTS 
 
Description of the study population 
There were 108 women in the HBPM group, of whom 29 recorded their results on the 
smartphone app (App-HBPM) and 79 them in their medical notes (Non-app HBPM). The 
control group comprised of 58 patients. Details of patient demographics, diagnosis at the 
beginning of the blood-pressure monitoring and at the end of the pregnancy and the duration 
of monitoring are outlined in Tables 3 and 4. When compared as three separate groups, 
there were significant differences in body mass index (BMI) at booking (P = 0.05), ethnicity 
(P < 0.05) and initial diagnosis (P < 0.05) between the groups (Table 3). Women in the App-
HBPM group had a higher BMI, were more likely to be of Afro-Caribbean ethnicity and have 
chronic hypertension as initial diagnosis (Table 3). When all the HBPM patients were 
combined as one group and compared with the control group, there were no significant 
differences in maternal age (P = 0.185), BMI (P = 0.986), ethnicity (P > 0.05), parity (P = 
0.871) or smoking status (P = 0.673) (Table 4); the differences in the underlying diagnosis 
remained, with significantly more women in the HBPM group having chronic hypertension 
(49.1% vs 25.9%, P = 0.004). The HBPM group had significantly longer duration of 
monitoring (9 weeks vs 5 weeks, P = 0.004) and started monitoring at an earlier gestation 
(30 weeks vs 33.6 weeks, P = 0.001) compared with the control group. 
 
Direct cost comparison of the study dataset 
The App-HBPM cohort had significantly fewer visits to the DAU over the course of the 
monitoring compared with the Non-App and control groups (median (IQR), 1 (0-11) vs 5 (0-
14) and 6 (0-18), respectively; P < 0.001) but had significantly more attendances to the 
hypertension clinic (P < 0.001). There were no differences in the number of midwifery clinic 
(P = 0.14), obstetric clinic (P = 0.19), GP (P = 0.67) or triage (P = 0.12) visits (Table 5). The 
costs per patient and patient per week based on this direct comparison of used services are 
shown in Table 6. The mean saving per week for the HBPM compared with the control group 
was £200.69 and for the App-HBPM cohort, the saving per week compared with the control 
group was £286.53. 
 
Process modelling 
Based on the calculations shown in Figure 1, the cost saving by using HBPM instead of 
traditional monitoring for scenario 1 was between £98.32 and £245.80 depending on the 
number of visits reduced. For scenario 2, the admission to hospital was modelled to be an 
infrequent occurrence and therefore a potential reduction in the number of bed days would 
incur significant savings. 
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DISCUSSION 
Summary of study findings 
Our findings demonstrate that HBPM reduces the number of antenatal outpatient 
appointments for blood-pressure-related reasons in a hypertensive pregnant population 
when compared with a similar population managed according to existing local guidelines, 
and therefore, reduces the cost of blood-pressure monitoring per patient per week. We have 
demonstrated these findings using two methods of cost evaluation: direct cost comparison of 
the study dataset and process scenario modelling. There was no difference in the number of 
adverse maternal, fetal or neonatal outcomes between the two groups. Sub-analysis of the 
HBPM cohort suggests that the adjunct of a smartphone app could further reduce the cost of 
monitoring per patient, per week. 
 
Interpretation of study findings and comparison to the existing literature 
 
The findings of the study demonstrate that HBPM appears to be a cost-saving alternative to 
traditional monitoring. These findings are likely to be important to the clinicians, patients and 
policy-makers. Similar cost analysis has been performed in other areas of obstetrics. For 
example, in a study of home-monitoring for signs of preterm labor, Morrison et al. 
demonstrated cost savings.22 In a retrospective modelling study, Buysse et al. did include 
hypertensive women in their ‘high risk’ cohort, but the analysis included all the diagnoses 
together and the savings predicted were hypothetical.23 Our findings of a reduction in the 
hospital visits with HBPM without an increase in adverse outcomes are supported by 
previous studies of HBPM in hypertensive and normotensive pregnant women.12,24-26 
 
Study strengths and limitations 
Our study has several strengths. Firstly, the fact that the control group were managed 
without the knowledge of being included in a cost analysis could potentially reduce the risk of 
bias, as it gives a true reflection of the cost of current management. Secondly, two different 
methods of cost evaluation were used. The consistent finding of cost reduction in the HBPM 
group gives further credibility to the concept that HBPM is cost-saving compared with 
traditional monitoring. Finally, the two groups were similar in terms of maternal 
demographics. This is important when comparing not only the cost of monitoring but also the 
adverse outcomes between the groups. For example, if the HBPM group had a lower 
proportion of smokers and obese patients compared with the control group (risk factors for 
adverse outcomes), this would not be a fair comparison. 
 
There are some limitations to our study. Although there was no difference in the maternal 
demographics between the two groups, there were differences in the underlying 
hypertensive disorder, with significantly more women with chronic hypertension in the HBPM 
cohort. The patients in this group were also monitored for a longer period. It is possible that 
these patients had a more stable disease process and were therefore deemed to require 
less frequent monitoring, influencing the number of visits and therefore cost of monitoring. 
Secondly, the process modelling technique of cost evaluation is based on several 
assumptions, for example, that every attendance to the DAU lasts for 60 min. We recognise 
that this may not be representative of real clinical situations, which vary over time due to 
several factors. In this study, we did not include the cost of anti-hypertensive medication or 
costs to the patient themselves in the cost evaluation. This is something to be considered in 
future studies. The results of our study relate only to antenatal practice in the UK and the 
cost savings therefore may not occur in other settings. Finally, it is possible that incorrect 
entries were recorded by patients and this could influence results. However, it is also 
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possible for healthcare professionals to document incorrectly a result. Bluetooth or wireless 
technology can resolve this potential problem by transmitting the result directly from device 
to output. 
 
Clinical and research implications 
 
Hypertensive disorders of pregnancy remain an important healthcare problem and cause of 
maternal morbidity and mortality. While advances have been made in recognising women at 
risk and offering preventive treatment,7,27,28 little has changed in the way women are 
monitored and treated once they have been diagnosed with hypertension in pregnancy. 
HBPM offers several advantages over traditional monitoring: it is more accurate and can 
allow for diagnosis of white-coat hypertension and masked hypertension, it offers autonomy 
to patients, allows for more frequent monitoring (patient’s check their blood pressure daily 
compared with two or three times a week in traditional monitoring) allowing sooner detection 
of hypertension and, from the findings of this study, it appears to be cost-saving. While our 
study may not be powered to assess differences in adverse outcomes, other small studies of 
HBPM in hypertensive pregnant women also reported no increase in adverse outcomes.24-26 
Our findings support the notion that a larger prospective study of HBPM in a hypertensive 
pregnant population is feasible and safe. Any such study should consider economic 
evaluation as part of its analysis. 
 
Innovation in healthcare, including the use of smartphone and remote monitoring technology 
has been recognised for its potential to improve patient care. The European Union eHealth 
action plan states that the development of mobile applications to support patients’ autonomy 
and provide a better quality of care should be a research priority.29 In their review article, 
Lanssens et. al demonstrate that the uptake of eHealth and telemonitoring has been 
relatively low in obstetrics, with only 14 studies identified.30 It is estimated that around 30% 
of the worldwide population own and use a smartphone whilst over 60% own and use a 
mobile phone with these figures projected to grow further.31 This highlights the potential for 
eHealth and innovative models of patient-centred care in both high- and low-income 
countries. 
 
Conclusions 
HBPM appears to be cost-saving compared with the traditional monitoring pathways in 
hypertensive pregnancies without any increase in the maternal, fetal or neonatal harm. 
Larger studies are now warranted to confirm these findings. If affirmed, such pathways have 
the potential to improve care for women with pregnancy hypertension worldwide. 
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Table 1 Cost inputs used in the study15-21 
 Cost/Year 
(£) 
Cost/hour or 
cost/interven
tion (£) 
Reference  
Midwife (Nurse Band 6) 32,114 44 Department of Health: 
NHS reference costs 
2015 to 2016 
Curtis, L. & Burns, A. 
(2016) 
General Practitioner (GP)  124 
Associate specialist 78,217 101 
Consultant (medical) 87,229 104 
Consultant (surgical) 88,684 105 
Mean costs for Doctor  103.33  
Ambulance Services  99 Department of Health: 
NHS reference costs 
2015 to 2016 
Triage 
-Nurse led  6.1 Curtis, L. & Burns, A. 
(2016) -Doctor led  14.4 
Blood Tests 
-Full blood count  2.65 
Akhtar, W. & Chung, 
Y., 2014 -Liver function tests   2.78 
-Renal function tests  2.12 
Fetal heart monitoring  27  
Day Case cost  698 Department of Health: 
NHS reference costs 
2015 to 2016 
Curtis, L. & Burns, A. 
(2016) 
Non-elective inpatient average cost 
excluding excess bed days 
 1,542 
The average cost of an excess bed 
day 
 283 
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Table 2 Modelling Scenarios for the HBPM and traditional monitoring pathways 
HBPM: Home blood pressure monitoring; CTG: cardiotocography
 Scenario 1: woman with 
mild/moderate hypertension 
requiring ongoing outpatient 
assessment 
Scenario 2: woman with 
moderate/severe 
hypertension requiring 
admission to initiate 
treatment/control BP 
Traditional 
monitoring 
pathway 
DAU 2-3 times/week: 
Midwife review 
BP Profile 
Blood Tests 
Fetal CTG 
 
Doctor Review     (20 minutes) 
Admission to hospital 
Blood tests 
Fetal CTG 
 
Inpatient costs/day 
HBPM pathway DAU 1-2 times/fortnight: 
Midwife review 
BP Profile 
Blood Tests 
Fetal CTG 
 
Doctor Review     (20 minutes)  
Admission infrequently 
required 
 
  (40 minutes) 
(40 minutes)
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Table 3 Demographic characteristics of the three study groups 
 App HBPM
(n=29) 
Non-App 
HBPM 
(n=79) 
Control 
(n=58) 
P
Maternal age (years) 32.0 (28.0-38.0) 33.0 (29.0-
37.0) 
32.0 (28.0-
35.3) 
0.41 
Body mass index (Kg/m2) 29.4 (25.6-39.0) 27.1 (23.6-
31.8) 
27.9 (24.9-
31.2) 
0.05 
Ethnicity 
  Caucasian 
  Afro-Caribbean 
  Asian 
  Mixed/other 
 
10 (34.5) 
10 (34.5) 
8 (27.6) 
1 (3.4) 
 
59 (74.7) 
10 (12.7) 
8  (10.1) 
2 (2.5) 
 
38 (65.5) 
13 (22.4) 
7 (12.1) 
0 (0) 
 
0.001 
0.35 
0.59 
0.419 
Nulliparous 13 (44.8) 48 (60.8) 32 (55.2) 0.331 
Smoker 2 (6.9) 1 (1.3) 1 (1.7) 0.223 
Assisted conception 1 (3.4) 5 (6.3) 1 (1.7) 0.405 
Gestational age at first visit 
(weeks) 
22.0 (15.8-27.5) 32.0 (24.9-
36.1) 
33.6 (28.2-
36.2) 
<0.001 
Duration of monitoring (weeks) 17 (10.9-23.3) 6.4 (2.6-12.0) 5.0 (3.3-9.3) <0.001 
Initial Diagnosis 
  Chronic hypertension 
  Gestational hypertension 
  History of pre-eclampsia 
  White-coat hypertension 
 
21 (72.4) 
2 (6.9) 
4 (13.8) 
2 (6.9) 
 
32 (40.5) 
45 (57) 
2 (2.5) 
0 (0) 
 
15 (25.9) 
37 (63.8) 
4 (6.9) 
2 (3.4) 
 
<0.001 
<0.001 
0.088 
0.095 
Final Diagnosis 
  Chronic hypertension 
  Gestational hypertension 
  Pre-eclampsia 
  Normotensive 
  White-coat hypertension 
 
16 (55.2) 
2 (6.9) 
 5 (17.2) 
5 (17.2) 
1 (3.4) 
 
27 (34.2) 
31 (39.2) 
17 (21.5) 
3 (3.8) 
1 (1.3) 
 
11 (19) 
25 (43.1) 
20 (34.5) 
2 (3.4) 
0 (0) 
 
0.003 
0.002 
0.124 
0.020 
0.380 
Values are given as median (interquartile range) or n (%). 
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Table 4 Demographic characteristics at inclusion and diagnoses in hypertensive pregnant 
women using home blood-pressure monitoring (HBPM) and in hypertensive controls 
managed according to local protocol 
 HBPM 
(n=108) 
Control  
(n=58) 
P 
Maternal age (years) 32.5 (29.0-37.8) 32 (28.0-35.3) 0.185 
Body mass index (Kg/m2) 27.7 (23.8-33.2) 27.9 (24.9-31.2) 0.986 
Ethnicity 
  Caucasian 
  Afro-Caribbean 
  Asian 
  Mixed/other 
 
69 (63.9) 
20 (18.5) 
16 (14.8) 
3 (2.8) 
 
38 (65.5) 
13 (22.4) 
7 (12.1) 
0 (0) 
 
0.834 
0.549 
0.625 
0.200 
Nulliparous 61 (56.5) 32 (55.2) 0.871 
Smoker 3 (2.8) 1 (1.7) 0.673 
Assisted conception 6 (5.6) 1 (1.7) 0.242 
Gestational age at first visit (weeks) 30.0 (22.0-35.0) 33.6 (28.2-36.1) 0.001 
Duration of monitoring (weeks) 8.9 (3.4-16.5) 4.9 (3.3-9.3) 0.004 
Initial diagnosis 
  Chronic hypertension 
  Gestational hypertension 
  History of pre-eclampsia 
  White-coat hypertension 
 
53 (49.1) 
47 (43.5) 
6 (5.6) 
2 (1.9) 
 
15 (25.9) 
37 (63.8) 
4 (6.9) 
2 (3.4) 
 
0.004 
0.013 
0.729 
0.522 
Final diagnosis 
  Chronic hypertension 
  Gestational hypertension 
  Pre-eclampsia 
  Normotensive 
  White-coat hypertension 
 
43 (39.8) 
33 (30.6) 
22 (20.4) 
8 (7.4) 
2 (1.9) 
 
11 (19) 
25 (43.1) 
20 (34.5) 
2 (3.4) 
0 (0) 
 
0.006 
0.106 
0.046 
0.307 
0.543 
Values are given as median (interquartile range) or n (%). 
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Table 5 Average number of visits to services for blood-pressure-related reasons, per patient 
according to the study groups 
 App-HBPM 
(n=29) 
Non-App 
HBPM  
(n=79) 
No HBPM 
(n=58) 
P 
Hypertension clinic 4.0 (2.0-7.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) <0.001 
Day assessment unit  1.0 (0.0-3.0) 5.0 (2.0-7.0) 6.0 (5.0-8.0) <0.001 
Maternity triage  0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.12 
General Practitioner 
appointments 
0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.67 
Midwifery clinic 
appointments 
0.0 (0.0-2.0) 0.0 (0.0-1.0) 0.0 (0.0-0.0) 0.14 
Obstetric clinic 
appointments 
0.0 (0.0-0.0) 0.0 (0.0-1.0) 0.0 (0.0-1.0) 0.19 
Values are given as median (interquartile range). HBPM, Home blood pressure monitoring 
 
 
Table 6 Average cost of monitoring per patient per week 
 App HBPM Non-App HBPM All HBPM No HBPM 
Average cost per patient £1244.29 £1853.56 £1692.56 £2275.26 
Average duration of 
monitoring (weeks) 
17.2 8.34 10.7 6.43 
Average cost per week 
 
£72.34 £222.25 £158.18 £358.87 
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Figure legends 
Figure 1 Cost-saving by using home blood-pressure monitoring (HBPM) instead of 
traditional monitoring, using economic modelling method 
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